CMPX – compass therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Compass Therapeutics (CMPX) had its "buy" rating reaffirmed by Guggenheim. They now have a $12.00 price target on the stock.
Compass Therapeutics: Potential Here, But Patience Required [Seeking Alpha]
Compass Therapeutics (CMPX) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Compass Therapeutics (CMPX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Compass Therapeutics (CMPX) had its "outperform" rating reaffirmed by William Blair.
Form S-8 Compass Therapeutics,
Form 10-K Compass Therapeutics, For: Dec 31
Form 8-K Compass Therapeutics, For: Mar 05
Form SCHEDULE 13G/A Compass Therapeutics, Filed by: Blackstone Holdings II L.P.
Form 4 Compass Therapeutics, For: Feb 08 Filed by: Schuetz Thomas J.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.